Cite
HARVARD Citation
Grischke, E. et al. (n.d.). 329PAbemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET). Annals of oncology. p. . [Online].